BPMUF
Basilea Pharmaceutica AG
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
77.40
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
77.40
Prev close
77.40
Day high
77.40
Day low
77.40
Volume
100
Market cap
—
P/E (TTM)
—
52W range
59.29 – 77.40
Day trading desk
Gap from prior close
-0.00%
Prior close 77.40
VWAP
—
—
Relative volume
—
—
Session range
—
77.40 – 77.40
Position in range
—
—
ATR (14D)
0.91
1.17% of price
Prior day high
77.40
PDH
Prior day low
77.40
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+18.17%
+19.5%
1M
+28.41%
+24.7%
3M
+18.89%
+15.8%
6M
+9.01%
-2.1%
YTD
+22.37%
+10.1%
1Y
+14.24%
-5.8%
3Y
+54.80%
-19.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on BPMUF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $232.38M | $208.54M | $157.63M | $147.76M | +11.4% |
| Operating revenue | $232.38M | $208.54M | $157.63M | $147.76M | +11.4% |
| Cost of revenue | $39.32M | $38.68M | $26.79M | $24.60M | +1.7% |
| Gross profit | $193.06M | $169.86M | $130.84M | $123.16M | +13.7% |
| Research & development | $105.89M | $77.14M | $77.85M | $73.80M | +37.3% |
| Selling, general & admin | $35.62M | $31.54M | $33.78M | $30.82M | +12.9% |
| Total operating expense | $141.51M | $108.69M | $111.64M | $104.62M | +30.2% |
| Operating income | $51.55M | $61.18M | $19.20M | $18.54M | -15.7% |
| Net interest income | -$2.09M | -$2.93M | -$9.51M | -$9.52M | +28.7% |
| Pre-tax income | $45.88M | $60.26M | $10.46M | $12.10M | -23.9% |
| Tax provision | $5.63M | -$17.33M | $10.00K | -$45.00K | +132.5% |
| Net income | $40.24M | $77.59M | $10.45M | $12.15M | -48.1% |
| Net income to common | $40.24M | $77.59M | $10.45M | $12.15M | -48.1% |
| Basic EPS | 3.29 | 6.42 | 0.87 | 1.02 | -48.8% |
| Diluted EPS | 3.14 | 5.83 | 0.86 | 1.02 | -46.1% |
| EBIT | $49.23M | $64.60M | $21.66M | $21.95M | -23.8% |
| EBITDA | $51.05M | $66.34M | $23.24M | $23.05M | -23.0% |
| Basic shares | 12.24M | 12.09M | 11.99M | 11.86M | +1.2% |
| Diluted shares | 13.68M | 13.86M | 12.14M | 11.94M | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $159.80M | $120.70M | $59.90M | $84.70M | — | +32.4% |
| Cash & short-term investments | $159.80M | $120.70M | $59.90M | $84.70M | — | +32.4% |
| Accounts receivable | $13.49M | $8.88M | $27.89M | $33.15M | — | +52.0% |
| Inventory | $21.56M | $31.61M | $26.41M | $24.24M | — | -31.8% |
| Total current assets | $251.73M | $220.91M | $152.15M | $175.36M | — | +14.0% |
| Property, plant & equipment | $18.20M | $19.00M | $20.60M | $21.60M | — | -4.2% |
| Goodwill & intangibles | $371.00K | $374.00K | $548.00K | $578.00K | — | -0.8% |
| Total assets | $282.00M | $257.76M | $173.29M | $220.85M | — | +9.4% |
| Total current liabilities | $49.22M | $45.56M | $47.59M | $74.85M | — | +8.0% |
| Current debt | — | $0 | $15.45M | $37.47M | $123.50M | — |
| Long-term debt | $75.44M | $95.91M | $95.45M | $131.36M | — | -21.3% |
| Total debt | $89.22M | $111.67M | $128.61M | $187.14M | — | -20.1% |
| Total liabilities | $154.06M | $176.76M | $183.29M | $241.56M | — | -12.8% |
| Retained earnings | -$882.57M | -$923.29M | -$1.00B | -$1.01B | — | +4.4% |
| Shareholder equity | $127.94M | $81.00M | -$10.00M | -$20.71M | — | +58.0% |
| Working capital | $202.51M | $175.35M | $104.55M | $100.51M | — | +15.5% |
| Net tangible assets | $127.57M | $80.63M | -$10.55M | -$21.29M | — | +58.2% |
| Shares issued | 13.32M | 13.17M | 13.10M | 13.09M | — | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $40.24M | $77.59M | $10.45M | $12.15M | — | -48.1% |
| Depreciation & amortisation | $1.81M | $1.73M | $1.58M | $1.10M | — | +4.7% |
| Stock-based compensation | $5.24M | $5.07M | $4.76M | $3.60M | — | +3.4% |
| Change in working capital | $6.61M | $9.37M | -$5.22M | -$11.38M | — | -29.5% |
| Operating cash flow | $62.09M | $74.36M | $14.24M | $7.06M | — | -16.5% |
| Capital expenditure | -$2.86M | -$1.79M | -$1.03M | -$3.30M | — | -59.7% |
| Investing cash flow | -$2.86M | -$1.01M | -$1.03M | $91.65M | — | -183.1% |
| Share buybacks | — | $0 | -$381.00K | — | -$4.25M | — |
| Financing cash flow | -$21.43M | -$13.16M | -$57.30M | -$45.25M | — | -62.8% |
| Free cash flow | $59.23M | $72.57M | $13.21M | $3.75M | — | -18.4% |
| End cash position | $162.34M | $124.56M | $64.32M | $108.57M | — | +30.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $159.80M | $128.37M | $120.70M | +24.5% |
| Cash & short-term investments | $159.80M | — | $120.70M | — |
| Accounts receivable | $13.49M | — | $8.88M | — |
| Inventory | $21.56M | — | $31.61M | — |
| Total current assets | $251.73M | $217.47M | $220.91M | +15.8% |
| Property, plant & equipment | $18.20M | $17.50M | $19.00M | +4.0% |
| Goodwill & intangibles | $371.00K | $300.00K | $374.00K | +23.7% |
| Total assets | $282.00M | $248.85M | $257.76M | +13.3% |
| Total current liabilities | $49.22M | — | $45.56M | — |
| Current debt | — | — | $0 | — |
| Long-term debt | $75.44M | $81.98M | $95.91M | -8.0% |
| Total liabilities | $154.06M | — | $176.76M | — |
| Retained earnings | -$882.57M | — | -$923.29M | — |
| Shareholder equity | $127.94M | — | $81.00M | — |
| Working capital | $202.51M | — | $175.35M | — |
| Net tangible assets | $127.57M | $102.86M | $80.63M | +24.0% |
| Shares issued | 13.32M | 13.31M | 13.17M | +0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
69.07
+12.06% from price
SMA 20
65.86
+17.52% from price
SMA 50
62.51
+23.82% from price
SMA 100
65.28
+18.57% from price
SMA 200
66.06
+17.17% from price
EMA 12
69.72
+11.01% from price
EMA 26
66.36
+16.64% from price
EMA 50
64.86
+19.33% from price
RSI (14)
98.8
Overbought
MACD (12,26,9)
3.36
Hist 1.43
ATR (14)
0.91
1.17% of price
Realised vol 30D
51.0%
Annualised
Bollinger upper
76.45
20, 2σ
Bollinger lower
55.27
20, 2σ
50 / 200 cross
Death
62.51 vs 66.06
Trend bias
Above 200
+17.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.24
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
51.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.5%
Peak to trough
Max drawdown 5Y
-25.8%
Peak to trough
ATR 14
0.91
1.17% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Basilea Pharmaceutica (SWX:BSLN) Lifts Guidance Following Strong Half Year Results, Is It Fully Valued?
Simply Wall St. · 2d ago
Basilea Pharmaceutica Ltd (XSWX:BSLN) (H1 2026) Earnings Call Highlights: Revenue Surges 14% ...
GuruFocus.com · 5d ago
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
GlobeNewswire · 5d ago
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
GlobeNewswire · 18d ago
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
GlobeNewswire · 25d ago
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
GlobeNewswire · 87d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.